Highlights
What are the main findings?
- Myopia is a disease that necessitates a novel approach and the implementation of specific public health policies.
- There are factors that constitute present impediments to efforts to combat the myopia epidemic.
What are the implications of the main findings?
- Authors strongly advocate that eye care practitioners incorporate myopia management as a standard of care in their practice.
- In jurisdictions that have not yet done so, public health agencies and governments should implement policies that facilitate enhanced access to eye care services and the reduction in the cost of efficacious devices and pharmaceutical products, thereby contributing to impeding myopia progression.
Abstract
Myopia is now classified as a disease given that it may lead to significant complications such as retinal detachment, choroidal neovascularization, macular degeneration, posterior polar cataract, and glaucoma. Current interventions, which include pharmacological treatments and optical devices, are considered effective; however, they have limitations and unmet needs that require further research. This text presents the consensus reached by a group of international experts, including clinicians and researchers, to identify issues that remain to be resolved, as well as potential solutions that will help define myopia management 2.0. To be more precise, current interventions appear to reach a state of stabilization after the first year, demonstrating an incapacity to optimally manage the progression of myopia. In the absence of such optimized treatments, a multitude of issues need to be addressed, including the necessity for a better understanding of the drivers of eye growth; an improved way to educate parents and eye care professionals about myopia management options rather than merely correcting it; the enhancement of treatment algorithms to ensure greater personalisation; a broader promotion of life hygiene interventions; more research about the impact of treatment cessation; and the development of novel treatments that exhibit superior efficacy and are made readily available to the general population. Other suitable developments in the field include the creation of tools designed to accurately monitor the visual behavior of children with myopia. In addition, the potential of artificial intelligence to analyze large datasets, including identification of biomarkers are promising. Development of molecules to optimize the way they regulate retinal response to visual signals is also needed. The combination of these technologies with improved screening of patients at high risk and tailored interventions should result in improved outcomes for patients with myopia. Finally, following the example of authorities that have already adopted strict policies to control myopia—such as in China—other public agencies and governments should adopt regulations to help control this epidemic and ease access to eye care and efficient devices.
1. Introduction
Myopia represents the most prevalent cause of distance vision impairment worldwide, with an estimated current global prevalence of 1.4 billion people, constituting approximately 23% of the global population [1]. Projections indicate that by 2050 more than half of the global population may be myopic, with this figure expected to exceed 65% in East Asia [1]. In addition to an increase in the prevalence of myopia, the onset of this condition is being recorded in younger age groups [2], resulting in a prolonged duration of the disease and increased risk of progression and poorer outcomes [3]. Numerous hypotheses have been postulated to explain the increase in myopia prevalence. While genetic factors are indisputable, and their contribution to the prevalence of myopia is well-documented, alongside that of demographic factors [4], their impact remains comparatively negligible when considered in conjunction with environmental factors, such as reduced reading distance, increased time spent doing near work, especially on screens, and limited outdoor exposure [5,6,7,8,9]. Although optical and pharmacological interventions have demonstrated efficacy in managing myopia [10], they are insufficient to totally prevent the axial length elongation beyond normal physiological growth [11]. Progressive myopia is predominantly associated with this form of unwanted eye elongation, which can lead to significant complications. Myopes face an increased risk of visual impairment [12], retinal detachment [13,14], macular degeneration [15], early onset of cataract [15], and a form of glaucoma that is difficult to treat [15]. Consequently, myopia is now considered a disease [16], and it is imperative to intervene at any level of myopia [17], whether before or after its onset, to prevent adverse consequences in the future. Recently, the American Medical Association adopted a resolution confirming the nature of myopia as a disease and urging governmental agencies to cover the cost of eye examinations and to make it more affordable for patients to acquire efficient devices to manage their myopia. Many years ago, the Chinese government identified myopia as a national priority and has made tremendous efforts to implement effective strategies through its health agencies and educational system. Such efforts merit being cited as exemplary and should inspire all other countries worldwide. Whilst the objectives delineated are commendable, it is the opinion of the authors that eye care practitioners do not possess the complete array of tools necessary to intervene more effectively. There are still a few pieces missing from the puzzle before myopia management becomes a well-established standard of care around the world. To this point, the main objective of this experts’ consensus is to delineate what they perceived as the unmet needs of myopic patients, encompassing considerations of affordability and accessibility to eye care services and products. It further explores promising developments in myopia management and proffers recommendations for future research, development, and associated initiatives to enhance patients’ outcomes. The identification and resolution of these needs are needed to pave the way to define myopia management 2.0.
2. Methodology
The authors of this article are part of a group of experts recruited based on peer recommendations to discuss issues related to modern myopic management. They were asked to contribute their ideas to build this text, participated in its revision, and have approved the final version presented here. When differing viewpoints were expressed, the first author proposed revisions until a consensus was reached among all parties.
The authors do not assert that they have conducted a systematic review of the extant literature on myopia in recent years. They present rather a consensus view of the reality they wish to share, drawing on diverse and significant experiences in myopia management and perspectives from all regions of the world. Subsequent to the reconciliation of these perspectives, the points raised are substantiated by pertinent articles.
It is acknowledged that some readers may hold divergent views and may employ other credible sources and references to substantiate their disagreement. Any debate conducted in a manner that respects the integrity of opposing views, while drawing upon reliable sources, contributes to the advancement of scientific knowledge.
3. Current Understanding of Myopia
It is important to first establish what we know about the mechanism of myopia development in order to identify the unanswered questions that should be the focus of future research.
The typical threshold for a diagnosis of myopia is a refractive error of ≤−0.50 D and ≤−6.00 D [18] for high myopia. Under regular conditions, newborns have a hyperopic reserve that will calibrate the emmetropization process [19]. The development of emmetropia is mostly driven by the retinal local response to visual signals (blur, contrast) [20] and exposure to a spectrum of spatial frequencies and chromatic cues [21]. The retina can then detect the contrast and the shape of the images and whether they are in focus or not. The retinal response dictates how the eye will react and adjust its shape and size, notably using cues from the chromatic aberrations perceived to start or limit its growth. When the eye remains emmetropic, the process is identified as retinal homeostasis [22,23]. When homeostasis is altered, the hyperopic reserve is consumed more rapidly, leading to the development of a refractive error. Axial length growth is no longer compensated by the other structures of the eye, and the refractive power of the eye is no longer emmetropic. Axial elongation exceeding physiological growth of an emmetropic eye is the primary sign of myopic progression [24]. Before myopia onset, the variation in axial length will accelerate as the change in dioptric power may follow weeks/months/years after. The amount of axial length elongation is correlated with severity of myopic disease [25]. If left untreated, abnormal axial lengthening has the potential to continue to evolve, with a higher risk of ocular pathology and/or long-term visual impairment [12].
Choroidal Reaction to Visual Stimulation
It is possible to measure the retina’s response to an optical signal by examining the choroid’s reaction. In the case of positive stimulation, which prevents abnormal axial elongation, the retinal pigment epithelium (RPE) secretes molecules that are transmitted to the choroid via three main channels [26,27]. These molecules induce tissue swelling and stimulate increased blood flow, which also contributes to the thickening of the choroid. This choroidal reaction, in turn, leads to changes in the proteins and the matrix of the sclera [28] and its collagen fibers, which reorganize to make the tissue resistant to elongation. Conversely, a negative signal reaching the retina will cause the choroid to thin, the blood flow to be reduced, and the resulting hypoxia will trigger a different rearrangement of the scleral fibers, making the sclera softer and thus allowing the eye to elongate more easily.
It would therefore be theoretically possible to link medium- and long-term retinal responses to the efficacy of an optical device or a medication, via short-term choroidal thickening or thinning [29,30]. However, this type of measurement must be performed with caution, taking into account the repeatability of the measurements (they must be taken at the same time of day, with the same instrument, under the same circumstances), the diurnal variation that affects this tissue, as well as physical activity, food intake, lighting environment, or any other factor that may influence blood flow and choroidal response. In a clinical setting, as a conservative estimate, a variation of 8 to 15 microns is considered to be within the measurement’s margin of error and consequently not clinically significant. In research, under a strictly controlled environment, smaller variations may be considered clinically relevant.
Several studies have referred to this methodology [31,32,33,34], although it is still not a standard established procedure. However, it was suggested that a reduction in axial length during the first few weeks after wearing orthokeratology lenses or defocus/diffuse-optics glasses may predict the long-term success of this strategy. As such, environmental, optical, and pharmaceutical strategies to manage myopia aim to restore retinal homeostasis in order to re-establish emmetropic eye growth. This is especially important to prevent the development of high myopia, in which axial elongation is greater, choroidal thinning more pronounced, and the risk of severe and sight-threatening complications greater [35,36].
Other examples of structural adaptation exist in relation to choroidal measurements. One study examined changes in ciliary muscle thickness after one week of 1% atropine treatment in children. The results of this study demonstrated a short-term mechanistic response rather than a long-term change. The significance of this modification remains unclear in light of efficient myopia management [37].
There are, however, cases where the retinal response remains insufficient (similar to non-treated myopic eyes) or falls well short of what was expected (over physiological natural eye growth at a given age). The mechanisms described here could therefore be supplemented by further discoveries that might improve the homeostatic model that has been developed. Other biomodulators could be identified as having a more positive influence on the response of the on and off cells of the retina, thereby leading to the development of nutritional supplements or pharmacological molecules aiming to provide a better management of axial elongation. Filters or light therapies influencing the contrast or chromatic cues could also contribute. All of these hypotheses require validation through research, particularly involving humans and not limited to animal models. This research must also be conducted among diverse populations so that the results can be easily applied regardless of the patients’ living circumstances.
4. Current Interventions to Slow Myopia Progression
Pharmacological, optical, surgical, and light-based approaches have been investigated to correct myopia and slow myopia progression, in addition to lifestyle and environmental interventions. The implementation of these strategies is contingent upon the specific type of myopia being addressed, namely premyopia, progressive myopia in childhood or adulthood and syndromic myopia, as their respective evidence bases vary. For instance, outdoor exposure has been demonstrated to impede myopia onset, while its efficacy in altering myopia progression remains less obvious. Overall, each of these methods has proven effective. However, their effectiveness may be perceived as limited, as they do not all fully succeed in restricting axial growth to the level of natural emmetropic physiological growth, which remains the goal of myopia management. For the moment, in the absence of devices reaching a higher level of management, a combination of strategies can therefore be suggested, which complicates treatment and may reduce patient adherence.
No approach has truly stood out, and a vast majority share the characteristic of demonstrating their greatest effectiveness in the first year of exposure to these strategies [38]. Subsequently, some interventions will show a plateau effect compared to untreated myopic patients, while others will continue to alter axial growth, albeit at a slower rate. It is also the case that a certain percentage (between 10% and 20%) of patients do not appear to respond or are slow to respond to the proposed strategy [39], as if they were simply correcting their vision with single-vision lenses. In such cases, adjunct medication is often necessary, or a complete change in approach, though this does not guarantee greater success.
To further refine our understanding of the impact of varying the interventions, a longitudinal study design, in which a subset of the participant cohort transitions to a different strategy annually while others maintain their original approach, would be a valuable addition. The optimal methods for circumventing the plateau effect, which is currently being observed, may be elucidated by manipulating visual stimuli, with or without the administration of pharmacological agents.
It is important to identify the factors limiting actual efficacy and address them; otherwise, myopia management—though necessary—will not yield all the expected results. It is possible to do more and better control eye growth. It is time to move on to myopia management 2.0.
5. Barriers to Improve Efficacy: Unmet Needs
5.1. Myopia Management Is Still Not Standard of Care
Despite an abundance of available information, only a minority of practitioners recommend methods for slowing axial length progression [40]. They do not discuss the need to manage myopia with parents, nor do they adjust their visual examinations and continue to prescribe and provide single-vision lenses to evolving myopic patients, despite the scientific consensus about its consequences on ocular health.
When asked about their resistance factors, professionals reported a lack of training, a lack of consensus on the most beneficial approaches, and inconsistency in the measures used to evaluate the success of implemented strategies [41]. Some also indicate that they do not have the tools to talk to parents and convince them to consider myopia management devices for their children.
It is therefore recommended that:
- Professional organizations, universities, and public health agencies, who have not done so yet, define myopia management as a standard of care.
- It is also very important that manufacturers support eye care professionals without downplaying the effort and time required to manage myopia at the next level. For example, dismissing the need to measure axial length, an essential test, may seem to be a reassuring approach, but it does nothing to raise standards of practice and fails to convince even the most resistant practitioners to embrace the concept of myopia management. Although refraction is imperative for the diagnosis of myopia, measuring axial length at each visit for a young myopic patient must be considered the gold standard for evaluating its progression.
- Myopia being now recognized as a disease, eye care practitioners should treat it as they would do the other ocular diseases (like glaucoma).
The World Council of Optometry adopted a statement in which it defines the three elements of this standard of care [42]:
(1) Educate yourself as an eye care practitioner and the parents about myopia and its consequences.
(2) Adapt the examination of the patient to detect and assess all aspects related to myopia.
(3) Treat/manage it.
Compared to habitual clinical practice, the first two steps are not particularly difficult to implement. However, treatment may require more adaptation to be fully incorporated into current practice, as all members of the healthcare team should adopt the same approaches and standards to provide credible and consistent care to patients. If this is not possible, the patient is better managed if referred to a competent colleague able to provide this type of service. Thus, appropriate intervention should be standard practice for all eye care practitioners and recognized as such by government and third-party stakeholders. The development of tools to improve understanding of myopia and the need for intervention among the general public should also continue [43].
5.2. No Consensus on Treatment Algorithms and Results Reporting
Despite attempts to develop standardized clinical guidelines for the treatment of myopia [18,39,44,45,46,47], there is no clear consensus around one of them that could be defined as the standard. Each region has its own particularities, affecting patients, healthcare professionals, and available products. Each government and agency is regulating eye care practitioners differently. For example, they can be restricted in their therapeutic privileges to use or prescribe therapeutic drugs, which limits access and significantly increases the cost of delivering the services.
It is therefore not surprising that experts do not agree on a single model, although many of them favor a personalized approach to patient care. As a result, many practitioners in routine practice feel lost and are unsure how to begin implementing their strategies, despite their desire to move forward in this direction.
However, there is emerging agreement on the following elements, upon which it will undoubtedly be possible to build a consensus-based approach:
- Management strategies should be implemented as early as possible, even at the stage of premyopia.
- On average, all strategies, backed up by science, can be considered equally effective. The selection of a given one is based on the patient’s characteristics and, optimally, becomes personalized.
- Axial length, a measurement and not refractive evolution, must be identified as the best metric for assessing myopia risk and progression [48].
- Once implemented, the strategy must be evaluated on a regular basis to assess its effectiveness, while taking seasonal variations into account.
- This evaluation, like ideal clinical studies, should focus on the cumulative effect of the treatment and avoid relying on efficacy percentages [30].
- If these elements are widely accepted, the resulting unmet needs become clear:
- Researchers and manufacturers must adopt a uniform method of presenting results to enable comparisons and extrapolate research results in clinical terms.
- Clinical guidelines should be widely adopted by professional organizations and distributed to their members. Neutral, professional platforms should be supported to make them more accessible.
- The acquisition of equipment required for rigorous myopia monitoring (biometer, topographer) is lagging. Practitioners cite cost or lack of space. It is urgent to develop partnerships with industry to make these testing devices easy to acquire and use. At the same time, professionals should establish justified fees and try to convince government agencies, insurers and third-party payers to cover these specific examination costs, as strongly suggested by AMA recently.
- Adequate research funding should be provided by public agencies and the industry to better identify markers that allow for the early identification of at-risk patients and those whose myopia will progress rapidly.
- Such biomarkers must be validated in order to measure, in the short term, the effectiveness of a given strategy, based on the patient for whom it was prescribed.
5.3. When to Start and When to Stop
It is obvious that the appropriate management of myopia should start prior to the manifestation of symptoms [49]. However, the optimal timing for the cessation of treatment strategies remains less clear. Clinical guidelines should define stability of axial length growth, in clinical terms, and provide the standards that would enable practitioners to more effectively formulate their interventions.
Possible approaches have been posited as potential solutions to the issue; for instance, myopia could be considered stable if the axial length of the myopic eye has not changed over the past 2 years [50]. However, a significant number of young myopic adults continue to progress up to 1D between 20 and 50 years [51], even though their physical growth has long since ceased. The question therefore arises as to how we can identify those who will experience this slow but detrimental increase in axial length and who, in theory, would benefit from lenses or glasses that help manage myopia.
5.3.1. Novel Approaches
With limited studies available, the use of anti-glaucoma drugs as a future tool for these patients was recently brought up as a possibility, although their optic nerve remains healthy [52,53,54,55]. The generation of a gradient between intracranial (higher) and intraocular pressures (lower) has been hypothesized to assist the sclera in resisting elongation. This could represent a novel approach, but more clinical long-term evidence is needed to support it. At the very least, these patients should be monitored more closely than their peers of the same age who show no such changes. Those who progress may reach levels of high myopia, increasing the risk of ocular complications and visual impairment later in life.
5.3.2. Young Adults Evolving
There is a paucity of robust data on young myopic adults, and on the efficacy of the strategies employed on this population. Previous work has noted variations in the effectiveness of these strategies between younger (8–12) and older (12–18) cohorts, with the older group typically demonstrating a generally superior response compared to the younger cohort, which has been categorized as fast progressors [56,57,58,59]. There is an absence of conclusive evidence regarding the application of these strategies in adulthood.
In young adults, with documented progression, frequent follow-up visits should be scheduled, as it may become difficult to differentiate myopia-related ocular health impairment from physiological change induced by tissue stretching or corneal ectasia, more prevalent than we may think. Distinction between optic nerve modifications and early glaucoma changes is challenging to discern, and the use of advanced imaging, with or without artificial intelligence models, is required to facilitate diagnosis.
Recommendations:
- Products specifically designed for this age group will need to be developed with consideration for their different visual needs as well as their lifestyle and leisure habits.
- ○
- Ortho-k designs, for instance, must be adapted to minimize visually disturbing aberrations while keeping a high positive retinal signal when evening outdoor activities and driving are in play. It is risky to assume that this lens will fully correct vision throughout the day and adequately manage myopic progression in adults, given that screen time is increasing and sleep time is dwindling (less than 8 h/night habitually needed).
- ○
- Multifocal soft lens designs should be adapted for adult patients, whose vision progresses more slowly but still progresses, while accommodating their lifestyle. Options to adapt larger treatment zones while keeping sufficient defocus in the pupil would be considered optimal.
- ○
- The use of low-dose atropine in adults has been little studied, but its effects on accommodation could disrupt near work more significantly than in children. Similarly, photosensitivity could hinder work or leisure activities.
- Monitoring and referral of evolving young adults require more frequent follow-ups and advanced imaging assessments.
- Keratoconus/early corneal ectasia should be screened on a regular basis, including the assessment of the posterior corneal surface, especially in the presence of eye rubbing, atopic reactions or seasonal allergies.
5.4. Specific and Individual Cases
A uniform approach is not efficacious in this context. According to this aforementioned group of experts, it would be optimal if the products offer practitioners customisation options so that optical products can be better tailored to patients.
In this regard, software-based ortho-k lens design offers greater sophistication than standard lens designs, which are primarily developed for correction rather than myopia management. Similarly, the ability to adjust the concentration of atropine according to the patient’s needs is another approach to personalizing treatment.
Some designs of spectacle lenses respect these concepts and are aligned with the dose–response existing at the retinal level [60]. However, these are the exceptions more than the rule. Similar customized approaches should be developed for multifocal soft lenses designed for myopia management.
5.5. The Not So Habitual Cases
Further research is required to investigate the underlying causes of these atypical myopia cases for which there is still uncertainty regarding the effectiveness of the strategies developed for more common myopia cases.
5.5.1. Anisometropia
The case of myopic anisometropia, where one eye is significantly more myopic than the other, the latter being mildly hyperopic or emmetropic, is worthy of consideration. When managing myopia, neglecting the other eye often results in the “good” eye undergoing much greater axial length progression than the treated eye, thus disrupting this patient’s visual function. It seems more logical to expose both eyes to the same stimulation; however, this restricts and limits the possibilities of treatment. Further studies are required to determine the most efficacious approach for these patients.
5.5.2. Syndromic Myopia
It is also prudent to consider the case of syndromic myopia, which is characterized by the presence of severe myopia in early childhood [61]. While there is documented evidence of a link with neurological syndromes, a more systematic approach is required to determine the circumstances and tests to use for patient evaluation. Given the limited resources available in healthcare systems, it is important to identify cases that require further investigation and a multidisciplinary approach to management.
5.6. Improving Efficacy of Treatments
It is becoming urgent to ensure that patients receive the most appropriate customized treatment(s) at the most appropriate time and for a sufficient duration to influence myopic progression and prevent the development of pathologies. Despite all attempts and available designs, current treatments offer plateaued efficacy. It was hypothesized that an average cumulative effect of 1D saved from myopia progression could be achieved, which should reduce the risk of myopic maculopathy by 40% [62]. Based on the clinical experience of this group of experts, it is certainly possible to reach higher levels of efficacy with a better understanding of the disease and of the response mechanisms in place, as well as the use of optimized strategies.
In order to extend the benefits of the treatment, it is necessary to develop a new generation of optical devices, new pharmaceutical molecule formulations and safer light therapy devices in order to achieve rapid and durable stabilization. While this goal may seem ambitious, it is based first and foremost on a better understanding of each of the components influencing the retinal response, beyond simple peripheral defocus or contrast. Optimizing signal quality and, above all, targeting its action in the most sensitive region of the retina (6–10 degrees around the fovea) [63] seem to be realistic goals to achieve in the short and medium term.
5.6.1. Response vs. Non-Response
Many clinical studies, assessing various devices and low-dose atropine, show that 10–20% of subjects may not respond as expected (see previous definitions for response below expectations) to a given treatment [64,65,66,67,68]. This suggests that the response of these subjects may be delayed/different compared with others. The key distinction is between residual progression—how much a person progresses while treated—and treatment effect—how much less progression occurs because of treatment. A person can still progress substantially while benefiting from treatment [69]. It is then clear that studies can classify outcomes as success or failure using predefined thresholds. Success in one case may be considered a failure in another population, despite similar outcomes. It is also possible that the “dose” to which the retina of these “non-responders” is exposed may not be sufficient to induce a significant change compared with the natural progression of myopic eyes [70].
In clinical practice, it is important to first assess adherence to treatment before concluding that a strategy is not yielding the expected results. In cases of non-compliance, it is necessary to discuss the reasons for this occurrence, and it may be beneficial to explore alternative treatment options that are more aligned with the patient’s lifestyle (e.g., switching a patient wearing orthokeratology lenses to daily disposable soft contact lenses if their sleep cycle is less than 8 h). It is also crucial to measure refractive error under consistent conditions to ensure comparability. A refraction performed under cycloplegia is not necessarily equivalent to one performed without it. Studies also mention the average age of participants, but the expected results must be contextualized based on the actual characteristics of the patient (not the mean). Greater progression is expected in younger patients, even if their myopia management is effective. Ideally, one should compare—taking age and ethnicity into account—the progression in a treated patient with that of a comparable emmetropic patient. There are several ocular growth curves (axial length) that describe this trajectory in emmetropic individuals, which thus serve as a reference for establishing the true treatment’s efficacy.
Recommendations:
- Further research is essential to identify demographic or physiological factors that can be used to guide eye care professionals and their patients to the most appropriate treatment.
- New products should incorporate a dose–response mechanism, knowing that this is the way retina is working (higher defocus, better outcome) and also younger, faster progressors should be treated with higher doses of defocus to slow their growth [70].
- Before concluding that a patient is not responding to a given treatment, many factors must be explored.
5.6.2. Customization of the Products
Current multifocal soft lens options present a single approach (centered distance), predetermined optical design for all patients, and are not adapted to the patient’s refractive error, his need for higher defocus when needed, or pupil area. The ability to tailor lenses to a patient’s specific needs and physiological parameters may result in significant improvements in efficacy. If this type of design becomes a reality, offering practitioners the option to select from multiple options (zones, level of defocus, aberrations induced) may enable better matching of lens to an individual or calibrated to increase or to lower the dose of defocus/loss of contrast whenever it is needed.
Ortho-k allows for greater flexibility in adjusting the optics to ensure a proper fit. However, for low myopia, the extent to which addition can be generated is constrained by the patient’s ocular parameters when utilizing standard designs. Additionally, the optical zone size of the lens does not invariably translate into a precise treatment zone size on the subject’s cornea [71,72]. The size of the zone is also contingent on the myopia level to be corrected and the topographic and biomechanical characteristics of the cornea. Consequently, although lenses can be custom-made, it is challenging to predict precisely the exact optics that will be generated on the subject’s cornea.
5.6.3. Concept of Plus Power Ratio (PPR)
The concept of plus power ratio, defined as the percentage of the area of defocus that covers the pupil, has been identified as a metric of significance. Efficacy is improved when PPR reaches a level of more than 50%. Ensuring topography at each follow-up visit would provide valuable information for the monitoring of treatment and the calibration of the dose administered to the patient.
The concept of the plus power ratio, defined as the percentage of the area of defocus that covers the pupil, has been identified as a metric of significance [72]. It has been established that efficacy is enhanced when PPR exceeds 50%. Ensuring topography at each follow-up visit has been demonstrated to provide valuable information for the monitoring of treatment and the calibration of the dose administered to the patient.
5.7. Accessibility and Affordability of Treatment
No matter how efficient strategies are, if the cost of accessing services and devices is too high, professionals will only treat the wealthiest. This could widen the gap between people, which is undesirable in so-called modern societies. Equal opportunity depends on lifelong education and access to it, regardless of economic status. Vision is certainly the primary tool that allows everyone to learn and remain productive. The role of primary eye care professionals, such as optometrists and ophthalmologists, requires action that impacts community/populations health [73]. Myopia management as a standard practice should be considered part of it. Services should be made accessible and, if possible, covered by public health systems, as AMA suggested recently.
Access to treatments (including availability of products and the resources of eye care practitioners and dispensaries) is variable, and interventions are expensive and unaffordable for many families [74,75]. Incentives that allow patients to acquire products at a reduced cost, as recently implemented in various regions of China through the Volume-Based Procurement (VBP) initiatives, should also be cited as good practice. Following this exemplary approach, options should be available to enable lower-income families to benefit from appropriate and effective care. Furthermore, not all interventions are available in all regions: cultural barriers may exist for some options, creating hesitancy for both eye care professionals and patients.
Effectively preventing and managing myopia helps reduce the incidence of eye diseases later in life. Myopia is recognized as a factor in lost productivity that costs governments hundreds of millions of dollars. Investing in prevention and primary care is a much lower cost that helps keep people with myopia productive and able to support their families [76,77]. This should become a priority for all governments and health agencies around the world.
5.8. Understanding That Environment Dictates Ocular Response
Incorporating environmental and life hygiene strategies (as well as pharmacological or optical) interventions should also be recommended, as proven by the considerable reduction in myopia prevalence following increased outdoor time exposure for school children in Taiwan [78]. Likewise, the Canadian 24-Hour Movement Guidelines program [79] should be considered, involving physical activities, good sleep time and life hygiene, as participation was associated with a lower risk of myopia and myopic anisometropia [80].
However, it remains unclear why exposure to the outdoor environment protects against myopia onset. Light level and dopamine production cannot totally explain the benefits of being outdoors to prevent myopia. Being exposed to a spectrum of low and high contrasts, and high and low frequencies, seems to also contribute to maintaining retinal homeostasis. Discovering the exact underlying mechanisms and closer monitoring of the real-life exposure of myopic kids to their environment would provide important insights into our understanding of the eye’s response.
Outdoor exposure is also subject to the dose–response mechanism of the retina [81]; as such, identifying the minimal or optimal dose is crucial. Defining the outdoor environment—a park in a crowded city or a vast field in the countryside—is also helpful. Recent findings have shown that short-term exposure in a given environment may be better than a longer exposure under less favorable conditions [82].
There are also limitations to this recommendation for outdoor exposure. How can we reconcile this effective measure with climate change, which is one of the main causes generating extremely high temperatures in many parts of the world? Playing ball for two hours under the scorching sun, at temperatures exceeding 100 °F, is simply unrealistic. Technologies that replicate outdoor brightness, spatial frequencies and contrasts (and their benefits) indoors could mitigate this grim reality of our deteriorating environments. Public health agencies and government should also step up efforts to address the causes of global warming.
These unanswered questions limit progress in myopia management, and funding studies on these important aspects is desperately needed.
5.9. Compliance and Adherence
Compliance with treatment and strategies prescribed remains a challenge, especially among younger patients. Discontinuation of the ortho-k remains a concern, driven by discomfort and concerns about the potential risk of developing infectious keratitis [83,84]. Atropine low-dose, as a compound medication, is also associated with discomfort at instillation, which may drive a significant dropout rate. A novel formulation using heavy water and adding preservative agents may offer a better alternative with a pH similar to the tear’s pH [85]. Young adults have expressed lower satisfaction with multifocal lenses compared with younger children [86], owing to peripheral defocus, which may lead to lower adherence in the long term.
Rebound Effects
Rebound effects need to be better understood and used to develop effective discontinuation protocols. Soft multifocal contact lenses and defocue/contrast glasses have no rebound effect after discontinuing use. Stronger rebound effects have been reported with ortho-k [87]. Concentration-dependent rebound effects of atropine have also been reported [88], with weaker effects seen in older subjects and with lower concentrations. In the absence of consensus on the way to stop using low-dose atropine, clear recommendations and communication for treatment discontinuation will ensure greater confidence in the use of myopia interventions. In order to properly educate parents and patients, and also to better understand these phenomena, we need even more evidence than that published [89] regarding the long-term use of these strategies and how patients actually use them in real-world settings, rather than in randomized trials.
6. Investigative Treatments and Future Directions
6.1. Using Technology to Improve Strategies
Even with clear protocols for individualized decision-making in treatment selection, as well as using appropriate combinations of therapies, optimal outcomes with existing options are likely to be limited. Therefore, novel approaches will be necessary to maximize curative results. These are likely to combine technological advances and/or the targeting of novel mechanisms in myopia, stepwise improvements to existing interventions, better identification of risk factors and indicators of treatment success (or failure), and earlier intervention.
6.2. Improving Lens Designs
Improvements in lens designs are likely to continue. Spiral-based optical designs have been investigated in contact lenses [90] and spectacles [91]. The principle is to manipulate peripheral defocus, as spiral designs can create zones of relative myopic or hyperopic defocus on the peripheral retina. The counterintuitive use of negative lenslets in glasses proved to be as efficient as current designs [92]. It enhances the concept of chromatic aberration as a key player in interpreting the blur, regardless of the lenses generating it. This type of device can also stimulate retinal signaling, as the visual system interprets the altered focus and lower contrast, potentially sending biochemical signals that slow axial elongation.
6.3. Optical Aberrations
To enable truly individualized treatment, the ability to customize ocular parameters, including higher-order, spherical and chromatic aberrations and contrast, would enable delivery of the right “dose” for a specific patient without impacting his functional vision.
6.4. Real-World Tracking Devices
Other wearable devices, designed to measure objectively the wearer’s exposure to close work and outdoor exposure, rather than to affect or correct myopia, are under investigation. These typically attach to existing spectacles and continuously measure distances from the user to their screen or page and/or light exposure [93,94,95]. Such devices promise to provide clear and accurate data on time spent outdoors and participating in close work, to augment survey and patient-reported measures. Data from wearables offer valuable insights into environmental and lifestyle changes that might help improve outcomes for people with myopia. More practically speaking, integrating such devices with electronic devices could provide patients with immediate feedback, encouraging them to adjust their usage and behavior.
6.5. Light Therapies
Exposure to intense red light from lasers appeared to show some effectiveness, but it was also found that such a high energy dose exceeded current standards and could damage the health of photoreceptors. Further studies are therefore needed, especially looking for other sources of illumination and/or other wavelengths.
Violet light therapy is an investigational treatment based on the understanding of this wavelength as the protective aspect of sunlight. Testing in animal models has demonstrated proof of concept [96,97], and violet light has now been investigated in small clinical studies in humans. These preliminary data—using spectacles that emit violet light for 3 h per day—show benefits in axial elongation and spherical equivalent refraction for violet light in comparison to non-emitting spectacles [98,99]. Exposure to blue light appears to have positive effects in the short term [100], but further studies are needed to understand longer-term efficacy, safety, and rebound effects, as long-term exposure to blue and violet light is considered detrimental for the visual system. Chromatic aberration cues also suggest that if the eye focuses more on the blue, it is driven to elongate. Filtering some blue light and favoring the exposure to violet light may be one interesting strategy to incorporate in optical devices.
6.6. Artificial Intelligence (AI)
Independent of therapeutic interventions, AI offers opportunities to analyze large datasets and help diagnosis, predict progression and individual risk, identify factors that affect efficacy or biomarkers of treatment success, assist biometry, improve the quality and speed of optical coherence tomography for segmentation and its analysis, and guide interventions in myopia [101,102]. A deep learning system has been developed to predict the onset of myopia using a large cohort of retinal images, with positive outcomes [103]. Systems that can predict response to treatment, quickly identify non-responders, and drive improvements in lens design have the potential to transform myopia care and assist clinicians with patient management. Another paper details why clinical implementation requires evidence that AI improved diagnostic and referral performance, beyond model discrimination alone [104]. In any case, caution is needed before training and using these models, as the sharing of patients’ clinical data must be strictly regulated to ensure its security.
6.7. Premyopes
Earlier screening, identification, and intervention in premyopic children is now under investigation. Children with premyopia—a spherical equivalent between ≤+0.75 D and >−0.50 D– have a greater risk of developing myopia, and preventing its development may improve later outcomes. Decisions about interventions for children without a formal diagnosis of myopia should be carefully considered, although for individuals with multiple risk factors for developing high myopia, early treatment to prevent this disease might be warranted.
6.8. Future Research
Significant gaps remain in our understanding and ability to treat myopia, which should be the focus of future research. Relatively little is known about the retinal reaction to the quality of the visual signal, although optimal optical devices will influence choroidal thickening. The choroid is a biomarker predicting the development of myopic macular degeneration, more accurate than age, axial length, and spherical equivalent [105,106], and greater choroidal thinning is correlated with the severity of myopic maculopathy [107]. Reductions in visual acuity in myopic maculopathy are significantly correlated with macular choroidal thickness [36]. Therefore, incorporation of choroidal measurements (considering limitations previously identified) and fundus photo analysis through AI programs into standard clinical practice should be prioritized, especially for patients with or at risk of high myopia.
Non-technological contributors to myopia progression also require further research, which is likely to identify lifestyle interventions that are less reliant on costs and to provide adjuncts to existing pharmacological and device therapies. Factors such as the immediate environment, level of lighting, reading distance, and contrast may affect the effectiveness of treatments. Trials should aim to assess environmental and lifestyle differences to maximize outcomes of existing therapies, such as the use of different treatments at different times of the year.
7. Conclusions
Significant advances in myopia treatment have been achieved in recent years, with greater understanding of the underlying pathophysiology. Current treatments, alone and in combination, are effective at slowing progression. The need to treat myopia early is well established, limiting future negative outcomes for patients. Despite this, current treatments are limited in efficacy after the first year of exposure, and many other efficient ones may be unavailable or unaffordable.
Further research is needed to make an individualized approach to myopia care a realistic goal. The current one-size-fits-all approach does not deliver optimal results for most patients. Nevertheless, the rate of improvements in myopia therapy continues at an exciting pace. Investigational therapies offer hope for greater choice and better efficacy in the future.
Author Contributions
Conceptualization, L.M.; methodology, L.M.; formal analysis, R.M.-C., P.S., T.-L.N., C.D.B., A.O., V.N., G.W. and A.M.-M.; writing—original draft preparation, L.M.; writing—review and editing, R.M.-C., P.S., T.-L.N., C.D.B., A.O., V.N., G.W. and A.M.-M. All authors have read and agreed to the published version of the manuscript.
Funding
The development of this article was supported by Basch + Lomb, including funding for medical writing support by Daniel Clarke, PhD and Lee-Jay Bannister, PhD, of Illuminate Medical. Industry had no role in topic selection or the formulation of conclusions.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
No new data were created or analyzed in this study.
Acknowledgments
During the preparation of this manuscript, the author(s) used the DeepL AI tool (Version 1.107.0) for the purposes of checking grammar and spelling. All authors attest that they meet the current International Committee of Medical Journal Editors (ICMJE) criteria for authorship and agree to be accountable for all aspects of the work.
Conflicts of Interest
LM: Research funds/honoraria received from Bausch and Lomb, Johnson and Johnson Vision Care, Cooper Vision, Contamac, Neurolens, Sight Glass, and Sydnexis. The funders had no role in the analyses performed or interpretation of data; in the writing of the manuscript; or in the decision to publish this consensus.
References
- Holden, B.A.; Fricke, T.R.; Wilson, D.A.; Jong, M.; Naidoo, K.S.; Sankaridurg, P.; Wong, T.Y.; Naduvilath, T.; Resnikoff, S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology 2016, 123, 1036–1042. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chen, Z.; Gu, D.; Wang, B.; Kang, P.; Watt, K.; Yang, Z.; Zhou, X. Significant myopic shift over time: Sixteen-year trends in overall refraction and age of myopia onset among Chinese children, with a focus on ages 4-6 years. J. Glob. Health 2023, 13, 04144. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Grzybowski, A.; Kanclerz, P.; Tsubota, K.; Lanca, C.; Saw, S.-M. A review on the epidemiology of myopia in school children worldwide. BMC Ophthalmol. 2020, 20, 27. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Theophanous, C.; Modjtahedi, B.S.; Batech, M.; Marlin, D.S.; Luong, T.Q.; Fong, D.S. Myopia prevalence and risk factors in children. Clin. Ophthalmol. 2018, 12, 1581–1587. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Alvarez-Peregrina, C.; Sánchez-Tena, M.Á.; Martinez-Perez, C.; Villa-Collar, C. The Relationship Between Screen and Outdoor Time With Rates of Myopia in Spanish Children. Front Public Health 2020, 8, 560378. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jones-Jordan, L.A.; Mitchell, G.L.; Cotter, S.A.; Kleinstein, R.N.; Manny, R.E.; Mutti, D.O.; Twelker, J.D.; Sims, J.R.; Zadnik, K. Visual activity before and after the onset of juvenile myopia. Investig. Ophthalmol. Vis. Sci. 2011, 52, 1841–1850. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Xiong, S.; Sankaridurg, P.; Naduvilath, T.; Zang, J.; Zou, H.; Zhu, J.; Lv, M.; He, X.; Xu, X. Time spent in outdoor activities in relation to myopia prevention and control: A meta-analysis and systematic review. Acta Ophthalmol. 2017, 95, 551–566. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Foreman, J.; Salim, A.T.; Praveen, A.; Fonseka, D.; Ting, D.S.W.; He, M.G.; A Bourne, R.R.; Crowston, J.; Wong, T.Y.; Dirani, M.; et al. Association between digital smart device use and myopia: A systematic review and meta-analysis. Lancet Digit Health 2021, 3, e806–e818. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bababekova, Y.; Rosenfield, M.; Hue, J.E.; Huang, R.R. Font size and viewing distance of handheld smart phones. Optom. Vis. Sci. 2011, 88, 795–797. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Logan, N.S.; Bullimore, M.A. Optical interventions for myopia control. Eye 2024, 38, 455–463. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Polling, J.R.; Klaver, C.; Tideman, J.W. Myopia progression from wearing first glasses to adult age: The DREAM Study. Br. J. Ophthalmol. 2022, 106, 820–824. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tideman, J.W.; Snabel, M.C.C.; Tedja, M.S.; van Rijn, G.A.; Wong, K.T.; Kuijpers, R.W.A.M.; Vingerling, J.R.; Hofman, A.; Buitendijk, G.H.S.; Keunen, J.E.E.; et al. Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia. JAMA Ophthalmol. 2016, 134, 1355–1363. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Han, X.; Ong, J.-S.; An, J.; Craig, J.E.; Gharahkhani, P.; Hewitt, A.W.; MacGregor, S. Association of Myopia and Intraocular Pressure With Retinal Detachment in European Descent Participants of the UK Biobank Cohort: A Mendelian Randomization Study. JAMA Ophthalmol. 2020, 138, 671–678. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- van Leeuwen, R.; Haarman, A.E.G.; van de Put, M.A.J.; Klaver, C.C.W.; Los, L.I. Dutch Rhegmatogenous Retinal Detachment Study Group. Association of Rhegmatogenous Retinal Detachment Incidence With Myopia Prevalence in the Neth-erlands. JAMA Ophthalmol. 2021, 139, 85–92. [Google Scholar] [PubMed]
- Haarman, A.E.G.; Enthoven, C.A.; Tideman, J.W.L.; Tedja, M.S.; Verhoeven, V.J.M.; Klaver, C.C.W. The Complications of Myopia: A Review and Meta-Analysis. Investig. Ophthalmol. Vis. Sci. 2020, 61, 49. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Board on Behavioral, Cognitive, and Sensory Sciences; Committee on Focus on Myopia: Pathogenesis and Rising Incidence. Myopia: Causes, Prevention, and Treatment of an Increasingly Common Disease; The National Academies Press: Washington, DC, USA, 2024; p. 374. [Google Scholar]
- Flitcroft, D.I. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog. Retin Eye Res. 2012, 31, 622–660. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Flitcroft, D.I.; He, M.; Jonas, J.B.; Jong, M.; Naidoo, K.; Ohno-Matsui, K.; Rahi, J.; Resnikoff, S.; Vitale, S.; Yannuzzi, L.; et al. IMI—Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. Investig. Ophthalmol. Vis. Sci. 2019, 60, M20–M30. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tahhan, N.; Bullimore, M.A.; He, X.; Ostrin, L.A.; Gawne, T.J.; Gifford, K.L.; Kang, P.; Morgan, I.; Couturier, A.; Ohno-Matsui, K.; et al. IMI-2025 Digest. Investig. Ophthalmol. Vis. Sci. 2025, 66, 27. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rozema, J.; Dankert, S.; Iribarren, R. Emmetropization and nonmyopic eye growth. Surv. Ophthalmol. 2023, 68, 759–783. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Flitcroft, D.I.; Harb, E.N.; Wildsoet, C.F. The Spatial Frequency Content of Urban and Indoor Environments as a Potential Risk Factor for Myopia Development. Investig. Ophthalmol. Vis. Sci. 2020, 61, 42. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wallman, J.; Winawer, J. Homeostasis of eye growth and the question of myopia. Neuron 2004, 43, 447–468. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rozema, J.J.; Farzanfar, A. Refractive development II: Modelling normal and myopic eye growth. Ophthalmic Physiol. Opt. 2025, 45, 120–134. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Saw, S.M.; Gazzard, G.; Shih-Yen, E.C.; Chua, W. Myopia and associated pathological complications. Ophthalmic Physiol. Opt. 2005, 25, 381–391. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Fan, Q.; Wang, H.; Jiang, Z. Axial length and its relationship to refractive error in Chinese university students. Cont. Lens Anterior Eye 2022, 45, 101470. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yang, J.; Ouyang, X.; Fu, H.; Hou, X.; Liu, Y.; Xie, Y.; Yu, H.; Wang, G. Advances in biomedical study of the myopia-related signaling pathways and mechanisms. BioMed Pharmacother. 2022, 145, 112472. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Brown, D.M.; Mazade, R.; Clarkson-Townsend, D.; Hogan, K.; Roy, P.M.D.; Pardue, M.T. Candidate pathways for retina to scleral signaling in refractive eye growth. Exp. Eye Res. 2022, 219, 109071. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhang, Y.; Phan, E.C.F. Wildsoet, Retinal Defocus and Form-Deprivation Exposure Duration Affects RPE BMP Gene Ex-pression. Sci. Rep. 2019, 9, 7332. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ostrin, L.A.; Harb, E.; Nickla, D.L.; Read, S.A.; Alonso-Caneiro, D.; Schroedl, F.; Kaser-Eichberger, A.; Zhou, X.; Wildsoet, C.F. IMI-The Dynamic Choroid: New Insights, Challenges, and Potential Significance for Human Myopia. Investig. Ophthalmol. Vis. Sci. 2023, 64, 4. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Brennan, N.A.; Toubouti, Y.M.; Cheng, X.; Bullimore, M.A. Efficacy in myopia control. Prog. Retin Eye Res. 2021, 83, 100923. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Walline, J.J.; Lindsley, K.; Vedula, S.S.; Cotter, S.A.; Mutti, D.O.; Twelker, J.D. Interventions to slow progression of myopia in children. Cochrane Database Syst. Rev. 2011, 12, CD004916. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lawrenson, J.G.; Shah, R.; Huntjens, B.; E Downie, L.; Virgili, G.; Dhakal, R.; Verkicharla, P.K.; Li, D.; Mavi, S.; Kernohan, A.; et al. Interventions for myopia control in children: A living systematic review and network meta-analysis. Cochrane Database Syst. Rev. 2023, 2, Cd014758. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Youssef, M.A.; Shehata, A.R.; Adly, A.M.; Ahmed, M.R.; Abo-Bakr, H.F.; Fawzy, R.M.; Gouda, A.T. Efficacy of Repeated Low-Level Red Light (RLRL) therapy on myopia outcomes in children: A systematic review and meta-analysis. BMC Ophthalmol. 2024, 24, 78. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Xiao, J.; Pan, X.; Hou, C.; Wang, Q. Changes in Subfoveal Choroidal Thickness after Orthokeratology in Myopic Children: A Systematic Review and Meta-Analysis. Curr. Eye Res. 2024, 49, 683–690. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Du, R.; Xie, S.; Igarashi-Yokoi, T.; Watanabe, T.; Uramoto, K.; Takahashi, H.; Nakao, N.; Yoshida, T.; Fang, Y.; Ohno-Matsui, K.; et al. Continued Increase of Axial Length and Its Risk Factors in Adults With High Myopia. JAMA Ophthalmol. 2021, 139, 1096–1103. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, Y.; Chen, S.; Lin, J.; Chen, W.; Huang, H.; Fan, X.; Cao, X.; Shen, M.; Ye, J.; Zhu, S.; et al. Vascular Changes of the Choroid and Their Correlations With Visual Acuity in Pathological Myopia. Investig. Ophthalmol. Vis. Sci. 2022, 63, 20. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Xiang, Z.Y.; Cui, L.-P.; Tang, C.; Zou, H.-D.; Xu, Y. Short-term effect of 1% atropine on the thickness of the ciliary muscle in children. Vis. Neurosci. 2025, 42, e022. [Google Scholar] [CrossRef] [Scilit]
- Bullimore, M.A.; Saunders, K.J.; Baraas, R.C.; Berntsen, D.A.; Chen, Z.; Chia, A.W.L.; Goto, S.; Jiang, J.; Lan, W.; Logan, N.S.; et al. IMI-Interventions for Controlling Myopia Onset and Progression 2025. Investig. Ophthalmol. Vis. Sci. 2025, 66, 39. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Saxena, R.; Dhiman, R.; Gupta, V.; Phuljhele, S.; Mahajan, A.; Rakheja, V.; Swaminathan, M.; Jethani, J.; Kesarwani, S.; Kekunnaya, R.; et al. Prevention and management of childhood progressive myopia: National consensus guidelines. Indian J. Ophthalmol. 2023, 71, 2873–2881. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wolffsohn, J.S.; Calossi, A.; Cho, P.; Gifford, K.; Jones, L.; Li, M.; Lipener, C.; Logan, N.S.; Malet, F.; Matos, S.; et al. Global trends in myopia management attitudes and strategies in clinical practice. Cont. Lens Anterior Eye 2016, 39, 106–116. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- McCrann, S.; Flitcroft, I.; Loughman, J. Is optometry ready for myopia control? Education and other barriers to the treatment of myopia. HRB Open Res. 2019, 2, 30. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Optometry, W.C.O. The Standard of Care for Myopia Management by Optometrists. 2021. Available online: https://myopia.worldcouncilofoptometry.info/standard-of-care/ (accessed on 16 March 2026).
- Kearney, S.; Coverdale, S.; Saunders, C.; Day, M.; Rountree, L.; Webber, K.; Mallen, E.A.H.; Ghorbani-Mojarrad, N. Perceptions and Barriers to Accessing Myopia Management in the UK. Children 2024, 11, 1490. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wolffsohn, J.S.; Flitcroft, D.I.; Gifford, K.L.; Jong, M.; Jones, L.; Klaver, C.C.W.; Logan, N.S.; Naidoo, K.; Resnikoff, S.; Sankaridurg, P.; et al. IMI—Myopia Control Reports Overview and Introduction. Investig. Ophthalmol. Vis. Sci. 2019, 60, M1–M19. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jonas, J.B.; Ang, M.; Cho, P.; Guggenheim, J.A.; He, M.G.; Jong, M.; Logan, N.S.; Liu, M.; Morgan, I.; Ohno-Matsui, K.; et al. IMI Prevention of Myopia and Its Progression. Investig. Ophthalmol. Vis. Sci. 2021, 62, 6. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tapasztó, B.; Flitcroft, D.I.; A Aclimandos, W.; Jonas, J.B.; De Faber, J.-T.H.N.; Nagy, Z.Z.; Kestelyn, P.G.; Januleviciene, I.; Grzybowski, A.; Vidinova, C.N.; et al. Myopia management algorithm. Annexe to the article titled Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur. J. Ophthalmol. 2024, 34, 952–966. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wildsoet, C.F.; Chia, A.; Cho, P.; Guggenheim, J.A.; Polling, J.R.; Read, S.; Sankaridurg, P.; Saw, S.-M.; Trier, K.; Walline, J.J.; et al. IMI—Interventions Myopia Institute: Interventions for Controlling Myopia Onset and Progression Report. Investig. Ophthalmol. Vis. Sci. 2019, 60, M106–M131. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rozema, J.; Dankert, S.; Iribarren, R.; Lanca, C.; Saw, S.-M. Axial Growth and Lens Power Loss at Myopia Onset in Singaporean Children. Investig. Ophthalmol. Vis. Sci. 2019, 60, 3091–3099. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lee, D.M.; Au Eong, J.T.; Au Eong, K.G. Prophylactic treatment of childhood myopia: A game-changer in combating the scourge of myopia? Front. Public Health 2025, 13, 1556199. [Google Scholar]
- Cw Klaver, C.; Polling, J.R.; Erasmus, G. Myopia Research, Myopia management in the Netherlands. Ophthalmic Physiol. Opt. 2020, 40, 230–240. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Brennan, N.A.; Cheng, X.; Bullimore, M.A. Adult Myopia Progression. Investig. Ophthalmol. Vis. Sci. 2024, 65, 49. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- El-Nimri, N.W.; Yao, M.; Huerta, A.; Hoang, M.; Wildsoet, C.F. Effect of chronic topical latanoprost on the sclera and lamina cribrosa of form-deprived myopic Guinea pigs. Exp. Eye Res. 2019, 186, 107740. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Beach, K.M.; Sah, R.P.; Jayakumar, J.P.J.; Paidimarri, S.; Manoharan, M.K.; Maldoddi, R.; Hung, L.-F.; She, Z.; Smith, E.L.; Ostrin, L.A. The effects of latanoprost on form-deprivation myopia. Investig. Ophthalmol. Vis. Sci. 2025, 66, 4543. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jang, K.; Lee, J.; Lee, K.; Kim, M.J.; Sohn, J. Effect of Anti-glaucoma Agents on Myopic Retinoschisis. Korean J. Ophthalmol. 2020, 34, 462–468. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wong, M.W.; Li, H.; Dan, Y.S.; Lor, S.C.; Soh, R.; Hoang, Q.V.; Chong, R.S. Associations between Intraocular Pressure or Glaucoma Medication with Axial Length and Pathologic Myopia Incidence and Progression. Ophthalmol. Sci. 2026, 6, 101061. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liu, Q.; Chen, Y.; Feng, Y.; Zhang, S.; Mao, X.; Xu, J. Comparison of two-year myopia control efficacy between spectacle lenses with highly aspherical lenslets and orthokeratology lenses. Contact Lens Anterior Eye 2025, 48, 102376. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zakova, M.; Fus, M.; Tejkl, L. Efficacy of Spectacle Correction Using Defocus Incorporated Multiple Segments in the Myopic Population. Clin. Ophthalmol. 2025, 19, 3191–3199. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, F.; Wang, W.; Yin, C.; Yang, S.; Zhan, X.; Chen, H.; Deng, J. Factors affecting myopia control outcomes with orthokeratology treatment in children: A retrospective anal-ysis. Front. Med. 2025, 12, 1580023. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pérez-Flores, I.; Macías-Murelaga, B.; Barrio-Barrio, J. Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression. Sci. Rep. 2023, 13, 16310. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Singh, N.K.; De Gracia, P. Next-Generation Spectacle Lenses for Myopia Control: Optical Designs, Mechanisms, and Clinical Efficacy. J. Clin. Med. 2025, 14, 7872. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Flitcroft, I.; Ainsworth, J.; Chia, A.; Cotter, S.; Harb, E.; Jin, Z.-B.; Klaver, C.C.W.; Moore, A.T.; Nischal, K.K.; Ohno-Matsui, K.; et al. IMI-Management and Investigation of High Myopia in Infants and Young Children. Investig. Ophthalmol. Vis. Sci. 2023, 64, 3. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bullimore, M.A.; Brennan, N.A. Myopia Control: Why Each Diopter Matters. Optom. Vis. Sci. 2019, 96, 463–465. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Swiatczak, B.; Scholl, H.P.N.; Schaeffel, F. Retinal “sweet spot” for myopia treatment. Sci. Rep. 2024, 14, 26773. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chua, W.H.; Balakrishnan, V.; Chan, Y.-H.; Tong, L.; Ling, Y.; Quah, B.-L.; Tan, D. Atropine for the treatment of childhood myopia. Ophthalmology 2006, 113, 2285–2291. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lam, C.S.Y.; Tang, W.C.; Tse, D.Y.-Y.; Lee, R.P.K.; Chun, R.K.M.; Hasegawa, K.; Qi, H.; Hatanaka, T.; To, C.H. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: A 2-year randomised clinical trial. Br. J. Ophthalmol. 2020, 104, 363–368. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cho, P.; Cheung, S.W. Retardation of myopia in Orthokeratology (ROMIO) study: A 2-year randomized clinical trial. Investig. Ophthalmol. Vis. Sci. 2012, 53, 7077–7085. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chamberlain, P.; Peixoto-De-Matos, S.C.; Logan, N.S.; Ngo, C.; Jones, D.; Young, G. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom. Vis. Sci. 2019, 96, 556–567. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Loh, K.L.; Lu, Q.; Tan, D.; Chia, A. Risk factors for progressive myopia in the atropine therapy for myopia study. Am. J. Ophthalmol. 2015, 159, 945–949. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Brennan, N.A.; Nixon, A.D.; Cheng, X.; Bullimore, M.A. Can we really distinguish ‘responders’ from ‘non-responders’ to myopia control interventions? Ophthalmic Physiol. Opt. 2024, 44, 1363–1367. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tuan, K.A.; Dillehay, S.M.; P.s. Group. Optical defocus to influence the progression of myopia and eye growth shows dos-age-dependance in children. In Proceedings of the Internation Myopia Conference, Sanya, China, 23–28 September 2024. [Google Scholar]
- Mountford, J. An analysis of the changes in corneal shape and refractive error induced by accelerated orthokeratology. Int. Contact Lens Clin. 1997, 24, 128–144. [Google Scholar] [CrossRef] [Scilit]
- Marcotte-Collard, R.; Simard, P.; Michaud, L. Analysis of Two Orthokeratology Lens Designs and Comparison of Their Optical Effects on the Cornea. Eye Contact Lens 2018, 44, 322–329. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Institute of Medicine (US) Committee on the Future of Primary Care; Donaldson, M.S.; Yordy, K.D.; Lohr, K.N.; Vanselow, N.A. Primary Care: America’s Health in a New Era; National Academies Press (US): Washington, DC, USA, 1999. Available online: https://www.ncbi.nlm.nih.gov/books/NBK232631/ (accessed on 15 March 2026).
- Agyekum, S.; Chan, P.P.; Adjei, P.E.; Zhang, Y.; Huo, Z.; Yip, B.H.K.; Ip, P.; Wong, I.C.K.; Zhang, W.; Tham, C.C.; et al. Cost-Effectiveness Analysis of Myopia Progression Interventions in Children. JAMA Netw. Open 2023, 6, e2340986. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Agyekum, S.; Chan, P.P.; Zhang, Y.; Huo, Z.; Yip, B.H.K.; Ip, P.; Tham, C.C.; Chen, L.J.; Zhang, X.J.; Pang, C.P.; et al. Cost-effectiveness analysis of myopia management: A systematic review. Front. Public Health 2023, 11, 1093836. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Fricke, T.R.; Sankaridurg, P.; Naduvilath, T.; Resnikoff, S.; Tahhan, N.; He, M.; Frick, K.D. Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia. Br. J. Ophthalmol. 2023, 107, 1043–1050. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pan, W.; Morgan, I.; Flitcroft, I.; Rose, K.; Ostrin, L.A.; Rosenfield, M.; Govender-Poonsamy, P.; Siu-Villaseñor, D.; Kaymak, H.; Khew, J.M.; et al. The need to address the myopia pandemic: Summary report of the global myopia public health summit 2024. Glob. Health Res. Policy 2025, 10, 45. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wu, P.C.; Chen, C.-T.; Poon, Y.-C.; Yang, Y.-H. Myopia Prevention and Outdoor Light Intensity in a School-Based Cluster Randomized Trial. Ophthalmology 2018, 125, 1239–1250. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tremblay, M.S.; Carson, V.; Chaput, J.-P. Canadian 24-Hour Movement Guidelines for Children and Youth: An Integration of Physical Activity, Sedentary Behaviour, and Sleep. Appl. Physiol. Nutr. Metab. 2016, 41, S311-27. [Google Scholar] [CrossRef] [Scilit]
- Zhong, H.; Zhu, H.; Jiang, M.; Mu, J. Adherence to the Canadian 24-hour movement guidelines and vision impairment in children and adolescents: A cross-sectional study. Front. Med. 2025, 12, 1523640. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ho, C.L.; Wu, W.F.; Liou, Y.M. Dose-Response Relationship of Outdoor Exposure and Myopia Indicators: A Systematic Review and Meta-Analysis of Various Research Methods. Int. J. Environ. Res. Public Health 2019, 16, 2595. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mei, Z.; Zhang, Y.; Jiang, W.; Lam, C.; Luo, S.; Cai, C.; Luo, S. Efficacy of outdoor interventions for myopia in children and adolescents: A systematic review and meta-analysis of randomized controlled trials. Front. Public Health 2024, 12, 1452567. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Van Meter, W.S.; Musch, D.C.; Jacobs, D.S.; Kaufman, S.C.; Reinhart, W.J.; Udell, I.J. Safety of overnight orthokeratology for myopia: A report by the American Academy of Ophthalmology. Ophthalmology 2008, 115, 2301–2313.e1. [Google Scholar] [PubMed]
- Charm, J.; Cho, P. High myopia-partial reduction ortho-k: A 2-year randomized study. Optom. Vis. Sci. 2013, 90, 530–539. [Google Scholar] [PubMed]
- Johnson, P.; Widder, K.; Cheetham, J.; Kirkeby, L. Methods and baseline of a large, multicenter, phase 3 study with low-dose atropine (SYD-101) for the treatment of myopia progression in over 800 children (STAR Study). Investig. Ophthalmol. Vis. Sci. 2025, 66, 2825. [Google Scholar]
- Ping, X.; Yoshioka, N.; Kim, J.; Sankaridurg, P. Subjective impressions with myopia control contact lenses versus single vision lenses: A systematic review and meta-analysis. Cont. Lens Anterior Eye 2025, 48, 102303. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chiu, Y.C.; Tsai, P.-C.; Lee, S.-H.; Wang, J.-H.; Chiu, C.-J. Systematic Review of Myopia Progression after Cessation of Optical Interventions for Myopia Control. J. Clin. Med. 2023, 13, 53. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wu, Y.; Chen, Y. Paradox of atropine in myopia control: Exploring dose-dependent efficacy, rebound effects, and optimal risk-benefit balance–a perspective. Front. Public Health 2026, 14, 1878312. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yam, J.C.; Zhang, X.J.; Zhang, Y.; Wang, Y.M.; Tang, S.M.; Li, F.F.; Kam, K.W.; Ko, S.T.; Yip, B.H.; Young, A.L.; et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology 2022, 129, 308–321. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Galinier, L.; Renaud-Goud, P.; Brusau, J.; Kergadallan, L.; Augereau, J.; Simon, B. Spiral diopter: Freeform lenses with enhanced multifocal behavior. Optica 2024, 11, 238–244. [Google Scholar] [CrossRef] [Scilit]
- Li, K.; Chen, X.; Liu, D.; Xing, Y.; Zhang, X.; Li, X.; Li, L.; Liu, Y. A spectacle lens design for myopia control and its optical performance analysis. In SPIE/COS Photonics Asia; SPIE: Washington, DC, USA, 2023; Volume 12765. [Google Scholar]
- Su, B.; Cho, P.; Vincent, S.J.; Zheng, J.; Chen, J.; Ye, C.; Wang, T.; Zhang, J.; Zhang, K.; Lu, F.; et al. Novel Lenslet-ARray-Integrated Spectacle Lenses for Myopia Control: A 1-Year Randomized, Double-Masked, Controlled Trial. Ophthalmology 2024, 131, 1389–1397. [Google Scholar] [PubMed]
- Williams, R.; Bakshi, S.; Ostrin, E.J.; Ostrin, L.A. Continuous Objective Assessment of Near Work. Sci. Rep. 2019, 9, 6901. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ramamurthy, D.; Paulraj, A.K.S.; Lakshmi, T.; Rajagopalan, T.; Lavanya, R. Development of smart spectacles to monitor and modify myopia-related health behaviour in children. Ophthalmic Physiol. Opt. 2023, 43, 517–524. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wen, L.; Cao, Y.; Cheng, Q.; Li, X.; Pan, L.; Li, L.; Zhu, H.; Lan, W.; Yang, Z. Objectively measured near work, outdoor exposure and myopia in children. Br. J. Ophthalmol. 2020, 104, 1542–1547. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Torii, H.; Kurihara, T.; Seko, Y.; Negishi, K.; Ohnuma, K.; Inaba, T.; Kawashima, M.; Jiang, X.; Kondo, S.; Miyauchi, M.; et al. Violet Light Exposure Can Be a Preventive Strategy Against Myopia Progression. EBioMedicine 2017, 15, 210–219. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jiang, X.; Pardue, M.T.; Mori, K.; Ikeda, S.-I.; Torii, H.; D’sOuza, S.; Lang, R.A.; Kurihara, T.; Tsubota, K. Violet light suppresses lens-induced myopia via neuropsin (OPN5) in mice. Proc. Natl. Acad. Sci. USA 2021, 118, e2018840118. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ullah, S.; Umer, M.F.; Chandran, S.P. Violet light transmission through eyeglasses and its effects on myopic children: A systematic review and meta-analysis. Saudi J. Ophthalmol. 2024, 38, 235–242. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Torii, H.; Mori, K.; Okano, T.; Kondo, S.; Yang, H.-Y.; Yotsukura, E.; Hanyuda, A.; Ogawa, M.; Negishi, K.; Kurihara, T.; et al. Short-Term Exposure to Violet Light Emitted from Eyeglass Frames in Myopic Children: A Randomized Pilot Clinical Trial. J. Clin. Med. 2022, 11, 6000. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Thakur, S.; Dhakal, R.; Verkicharla, P.K. Short-Term Exposure to Blue Light Shows an Inhibitory Effect on Axial Elongation in Human Eyes Independent of Defocus. Investig. Ophthalmol. Vis. Sci. 2021, 62, 22. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhang, J.; Zou, H. Insights into artificial intelligence in myopia management: From a data perspective. Graefes Arch. Clin. Exp. Ophthalmol. 2024, 262, 3–17. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Foo, L.L.; Ng, W.Y.; Lim, G.Y.S.; Tan, T.-E.; Ang, M.; Ting, D.S.W. Artificial intelligence in myopia: Current and future trends. Curr. Opin. Ophthalmol. 2021, 32, 413–424. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Qi, Z.; Li, T.; Chen, J.; Yam, J.C.; Wen, Y.; Huang, G.; Zhong, H.; He, M.; Zhu, D.; Dai, R.; et al. A deep learning system for myopia onset prediction and intervention effectiveness evaluation in children. npj Digit. Med. 2024, 7, 206. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wu, Y.; Qian, B.; Li, T.; Qin, Y.; Guan, Z.; Chen, T.; Jia, Y.; Zhang, P.; Zeng, D.; Moroi, S.; et al. An eyecare foundation model for clinical assistance: A randomized controlled trial. Nat. Med. 2025, 31, 3404–3413. [Google Scholar] [PubMed]
- Wu, H.; Peng, T.; Zhou, W.; Huang, Z.; Li, H.; Wang, T.; Zhang, J.; Zhang, K.; Li, H.; Zhao, Y.; et al. Choroidal vasculature act as predictive biomarkers of long-term ocular elongation in myopic children treated with orthokeratology: A prospective cohort study. Eye Vis. 2023, 10, 27. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Xiong, R.; Zhu, Z.; Jiang, Y.; Wang, W.; Zhang, J.; Chen, Y.; Bulloch, G.; Yuan, Y.; Zhang, S.; Xuan, M.; et al. Longitudinal Changes and Predictive Value of Choroidal Thickness for Myopia Control after Repeated Low-Level Red-Light Therapy. Ophthalmology 2023, 130, 286–296. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Midorikawa, M.; Mori, K.; Torii, H.; Tomita, Y.; Zhang, Y.; Tsubota, K.; Kurihara, T.; Negishi, K. Choroidal thinning in myopia is associated with axial elongation and severity of myopic maculopathy. Sci. Rep. 2024, 14, 17600. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.